MARKET IS CLOSED
Loading latest tickers...

Market Indices

S&P 500
$7,722.72
+0.73%
NASDAQ 100
$30,807.93
+1.00%
DOW JONES
$51,177.00
+0.49%
NASDAQ Composite
$27,190.86
+1.19%
RUSSELL 2000
$2,815.20
+0.90%
CBOE VIX
$15.31
-6.59%

Sector Heatmap

Technology+1.01%
Financials+0.06%
Healthcare-0.01%
Consumer Cycl+1.13%
Consumer Staples+0.25%
Energy+0.40%
Industrials+0.78%
Materials+0.66%
Real Estate+0.32%
Utilities+0.38%
Comm Services+0.35%

COAG — Hemab Therapeutics Holdings, Inc. Common Stock

Nasdaq

Hemab Therapeutics Holdings, Inc. Common Stock

CompareBack to Screener
$31.11
+0.05(+0.16%)
O
31.49
H
31.49
L
30.06
V
354.14K
⏱️ End-of-day dataAs of Oct 2, 2026
OverviewStatisticsFinancialsHistorical DataOptionsDividend HistoryNewsChart

Hemab Therapeutics Holdings, Inc. Common Stock Statistics

Total Valuation

Market Cap$1.62B
Enterprise Value$1.62B

Important Dates

Earnings Daten/a
Ex-Dividend Daten/a

Share Statistics

Current Share Classn/a
Shares Outstanding46.71M
Shares Change (YoY)n/a
Shares Change (QoQ)n/a
Owned by Insiders (%)n/a
Owned by Institutions (%)n/a
Floatn/a

Valuation Ratios

PE Ration/a
Forward PEn/a
PS Ration/a
Forward PSn/a
PB Ration/a
P/TBV Ration/a
P/FCF Ration/a
P/OCF Ration/a
PEG Ration/a

Enterprise Valuation

EV / Earnings-71,526.85
EV / Salesn/a
EV / EBITDA-68,937.92
EV / EBIT-68,724.78
EV / FCF-74,793.95

Financial Position

Current Ratio12.85
Quick Ration/a
Debt / Equity-0.00
Debt / EBITDA-0.02
Debt / FCF-0.02
Interest Coveragen/a

Financial Efficiency

Return on Equity (ROE)11.42%
Return on Assets (ROA)-12.94%
Return on Invested Capital (ROIC)n/a
Return on Capital Employed (ROCE)n/a
Weighted Average Cost of Capital (WACC)n/a
Revenue Per Employeen/a
Profits Per Employeen/a
Employee Countn/a
Asset Turnovern/a
Inventory Turnovern/a

Taxes

Income Tax$12
Effective Tax Raten/a

Stock Price Statistics

Beta (5Y)n/a
52-Week Price Change-8.50%
50-Day Moving Average$44.49
200-Day Moving Averagen/a
Relative Strength Index (RSI)13.09
Average Volume (20 Days)623,729

Short Selling Information

Short Interestn/a
Short Previous Monthn/a
Short % of Shares Outn/a
Short % of Floatn/a
Short Ratio (days to cover)n/a

Income Statement

Revenuen/a
Gross Profitn/a
Operating Income-$23.61K
Pretax Income-$22.68K
Net Income-$22.69K
EBITDA-$23.54K
EBIT-$23.61K
Loss Per Share$-0.51

Balance Sheet

Cash & Cash Equivalents$49.86K
Total Debt$519
Net Cash$49.34K
Net Cash Per Share$0.00
Equity (Book Value)-$198.62K
Book Value Per Share$-0.00
Working Capital$156.24K

Cash Flow

Operating Cash Flow-$22.37K
Capital Expenditures-$-112
Depreciation & Amortizationn/a
Net Borrowingn/a
Free Cash Flow-$21.70K
FCF Per Share$-0.00

Margins

Gross Marginn/a
Operating Marginn/a
Pretax Marginn/a
Profit Marginn/a
EBITDA Marginn/a
EBIT Marginn/a
FCF Marginn/a

Dividends & Yields

Dividend Per Sharen/a
Dividend Yieldn/a
Dividend Growth (YoY)n/a
Years of Dividend Growthn/a
Payout Ration/a
Buyback Yieldn/a
Shareholder Yieldn/a
Earnings Yieldn/a
FCF Yield0.00%

Analyst Forecast

Price Targetn/a
Price Target Differencen/a
Analyst Consensusn/a
Analyst Countn/a
Revenue Growth Forecast (3Y)n/a
EPS Growth Forecast (3Y)n/a

Fair Value

Lynch Fair Valuen/a
Lynch Upsiden/a
Graham Numbern/a
Graham Upsiden/a

Stock Splits

Last Split Daten/a
Split Typen/a
Split Ration/a

Scores

Altman Z-Scoren/a
Piotroski F-Scoren/a